• Wed news: 2025 Medicare drug price negotiations. BioAge Labs aiming at $180M IPO. Merck Keytruda colorectal cancer flop. Sanofi gets bids for consumer health unit. Novo Nordisk CEO in Senate hot seat. See more on our front page

One more time: We're not buying Valeant, Allergan CEO insists


<



Of course you are not. Your business model is unsustainable and your pipeline is dry. This is a no-win situation and the way out is no longer mergers with other companies to hide real growth. Again I am shorting this pig. From the CEO, to the board to the top leadership this company is mis-guided. To some of you, keep dreaming.